Navigation Links
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Date:5/3/2011

re forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 14, 2011. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... STAMFORD, Conn. , April 20, 2015 /PRNewswire/ ... announced that Alan Butcher has joined ... & Business Development. Alan will have responsibility for ... commercial, near-commercial, and development-stage products that would benefit ... bringing aboard a proven leader," said Purdue President ...
(Date:4/20/2015)... , April 20, 2015 Stand Up To Cancer (SU2C) ... a $20 million Dream Team to attack the number one ... Annual Meeting of the American Association for Cancer Research (AACR), ... 221,000 people in the United States ... and 158,040 will die from it, making lung cancer the ...
(Date:4/20/2015)... SAN DIEGO , April 20, 2015 /PRNewswire/ ... biotechnology company developing novel oncology and drug-delivery therapies, ... at the American Association for Cancer Research (AACR) ... interim results of its randomized Phase 2 study ... the annual meeting of the American Society of ...
Breaking Medicine Technology:Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5
... Company,s TPM Drug Delivery Technology Demonstrates Substantial Increase ... Leading Marketed Product -, MELBOURNE, Australia, April ... OTCQX: PPGNY) today,announced positive results of a pre-clinical ... for the targeted delivery of lidocaine,demonstrating increased efficacy ...
... Immunologics, Inc. ("QI"),announces the commencement of a Phase ... of a novel anti-cancer vaccine/immunotherapy that will,be used ... Patients accepted,into the study have previously failed to ... chemotherapy. QI has commissioned,the study to be done ...
Cached Medicine Technology:Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine 2Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine 3Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine 4Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas 2Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas 3
(Date:4/20/2015)... Genuine fat loss results can seem virtually ... in the past. But what failed dieters and gym-goers don’t ... guaranteed by adhering to five simple principles. , 1. Nutrition, ... many hours one spends working at the gym, a poor ... a nutritional mean plan does not mean starvation, calorie counting ...
(Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
(Date:4/20/2015)... Westchester County, New York (PRWEB) April 20, 2015 ... that the Centers for Medicare & Medicaid Services introduced ... of their HCAHPS (Hospital Consumer Assessment of Healthcare Providers ... This national survey asks patients about their experiences during ... current survey results from July 1, 2013 through June ...
(Date:4/20/2015)... The buttocks tend to become sore and ... from Longmont, Colo., decided that there needed to be ... use, compact and ideal for travelers and truck drivers, ... from becoming sore during travel via airplanes and vehicles. ... blood circulation, which helps to avoid blood clots. , ...
(Date:4/20/2015)... Columbia (PRWEB) April 20, 2015 Cannabix ... a hand-held Cannabix Marijuana Breathalyzer for law enforcement and ... the first publicly available images of its marijuana breathalyzer ... Cannabix Marijuana Breathalyzer. Media files and video that show ... for online viewing at cannabixtechnologies.com . , The ...
Breaking Medicine News(10 mins):Health News:Guarantee Fat Loss Results With 5 Easy Tips 2Health News:Guarantee Fat Loss Results With 5 Easy Tips 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 2Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 3Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 4
... (Nasdaq: MLNM ) today announced that its ... (ASH) meeting will be,webcast live and may be ... website, http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ... by Millennium senior management as,well as clinical investigators ...
... UNAIDS/WHO AIDS epidemic update released last week has revised the ... of the estimate for India to 2.5 million people living ... official estimate of 5.7 million people. This revision is based ... in India. , A commentary published in the Lancet on ...
... resolve ongoing debate , MONDAY, Dec. 3 (HealthDay News) ... B and the risk of developing multiple sclerosis (MS) in ... studies have investigated a possible association between the hepatitis B ... of increased short- or long-term risk of MS. However, ...
... St. Louis, Dec. 3, 2007 Psychiatry researchers at Washington ... a clinical diagnosis of alcohol dependence in young adults is ... "Some participants in the study reported 50 or 100 partners, ... that the more sex partners you have, the more likely ...
... Tucson Marathon Runners, PLEASANT GROVE, Utah, Dec. 3 ... inflammation and pain, but at the same time,worry about ... University and Vanderbilt University, published in,Medicine & Science in ... be unhealthy in the long term. The practice leads ...
... The American Association,of Colleges of Nursing (AACN) today ... entry-level baccalaureate nursing programs,increased by 4.98 percent from ... year of enrollment growth, the rate at which ... has declined sharply since 2003,when enrollment was up ...
Cached Medicine News:Health News:Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event 2Health News:Implications of the new HIV estimate for India 2Health News:No Link Between Hepatitis B Shot, MS: Study 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 3Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 2Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 3Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 4Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 5
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: